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Resolution of Inflammation Following Treatment of
Ankylosing Spondylitis Is Associated with New Bone
Formation
SUSANNE J. PEDERSEN, PRAVEENA CHIOWCHANWISAWAKIT, ROBERT G.W. LAMBERT, 
MIKKEL ØSTERGAARD, and WALTER P. MAKSYMOWYCH
ABSTRACT. Objective. To test the hypothesis that in patients with ankylosing spondylitis (AS) a vertebral corner
inflammatory lesion (CIL) visible on magnetic resonance imaging (MRI) that completely resolves
following treatment with anti-tumor necrosis factor-α (TNF-α) agents is more likely to develop into
a de novo syndesmophyte visible on a radiograph as compared to a vertebral corner with no CIL.
Methods. Fifty patients with AS, who had MRI at baseline and at followup (mean 19.2 months), and
spinal radiography at baseline and after 2 years, were followed prospectively. A persistent CIL was
defined as being present on both MRI, while a resolved CIL was defined as present at baseline MRI
and completely disappeared at followup MRI. Two readers read the MRI independently, and analy-
ses were done for areas with agreement (concordant reads) and for individual reads.
Results. For patients receiving anti-TNF therapy (n = 23), new syndesmophytes developed more fre-
quently from vertebral corners where a CIL had completely resolved on followup MRI (42.9% on
concordant reads) as compared to vertebral corners where no CIL was demonstrable on either the
baseline or followup MRI (2.4%; p < 0.0001). Results from individual readers showed similar dif-
ferences. For patients receiving standard treatment (n = 27), the same pattern, although nonsignifi-
cant, was observed (20% vs 3.3%; p = 0.16) on concordant reads, as well as on individual reads.
Conclusion. Our study of AS spines documents that MRI findings predict new bone formation on
radiograph. Demonstration of an increased likelihood of developing new bone following resolution
of inflammation after anti-TNF therapy supports the theory that TNF-α acts as a brake on new bone
formation. Because the number of new syndesmophytes was low, further study is necessary to make
firm conclusions. (J Rheumatol First Release April 1 2011; doi:10.3899/jrheum.100925)
Key Indexing Terms:
ANKYLOSING SPONDYLITIS             MAGNETIC RESONANCE IMAGING
INFLAMMATION BONE SPUR
From the Departments of Rheumatology, Gentofte and Glostrup
University Hospitals, Copenhagen, Denmark; the Faculty of Medicine,
Siriraj Hospital, Mahidol University, Thailand; and Departments of
Medicine and of Radiology and Diagnostic Imaging, University of
Alberta, Edmonton, Alberta, Canada.
Dr. Pedersen was supported as a doctoral candidate by the Faculty of
Health Sciences, University of Copenhagen, Denmark. Dr. Maksymowych
is a Scientist of the Alberta Heritage Foundation for Medical Research.
S.J. Pedersen, MD, Department of Rheumatology, Gentofte and Glostrup
University Hospitals; P. Chiowchanwisawakit, MD, Siriraj Hospital,
Mahidol University; R.G.W. Lambert, FRCPC, FACP, FRCP(UK),
University of Alberta; M. Østergaard, MD, PhD, DMSc, Glostrup
University Hospital; W.P. Maksymowych, MD, FRCPC, FACP,
FRCP(UK), University of Alberta.
Address correspondence to Dr. S.J. Pedersen, Department of
Rheumatology, Nordre ringvej57, DK-2600, Glostrup, Denmark. 
E-mail: susanne_juhl_ped@dadlnet.dk
Accepted for publication February 15, 2011.
Magnetic resonance imaging (MRI) demonstrates bone mar-
row edema in the sacroiliac joints and spine as a character-
istic feature of active inflammation in patients with anky-
losing spondylitis (AS)1,2. In the spine, inflammation is pri-
marily seen at the anterior and posterior vertebral corners,
i.e., the location where syndesmophytes develop. This has
led to the hypothesis that inflammation leads to new bone
formation in patients with AS. Three studies have demon-
strated a positive association between vertebral corner
inflammation on baseline MRI and subsequent development
of new syndesmophytes on radiographs 2 years later in
patients treated with tumor necrosis factor-α (TNF-α)
inhibitor3,4,5. The conclusion was based on baseline MRI
examination of patients recruited to clinical trials of anti-
TNF therapy while we also reported data from 1 followup
MRI evaluation in testing the hypothesis that persistent
inflammation at vertebral corners was more likely to lead to
new syndesmophytes4. Surprisingly, the converse was
observed. Inflammation that completely resolved on fol-
lowup MRI was more prone to develop into syndesmo-
phytes as compared to persistent inflammation in patients
taking anti-TNF therapy4. This observation may be
explained by TNF-α inducing Dickkopf-1 (DKK-1), a pro-
tein that downregulates the Wnt signaling pathway that
directs osteoblast formation from mesenchymal precursor
cells6. Inhibition of TNF-α would then lead to reduced
DKK-1 and thereby enhanced Wnt signaling, leading to for-
mation of new bone. Further, it has been shown that
osteoblast differentiation induced by bone morphogenetic
protein (BMP-2), which is also upregulated by Wnt signal-
ing, is attenuated by DKK-1 and DKK-27. Consequently, 1
prediction of this hypothesis is that new syndesmophytes are
more likely to develop after resolution of inflammation
induced by anti-TNF agents.
Our purpose was to examine the relationship between the
course of MRI inflammation and the subsequent develop-
ment of new syndesmophytes in an observational cohort of
patients with AS receiving anti-TNF therapy or standard
treatment with nonsteroidal antiinflammatory drugs
(NSAID) and physical modalities. In particular, we aimed to
test the hypothesis that a CIL visible on MRI that complete-
ly resolves following treatment is more likely to develop
into a de novo syndesmophyte than a vertebral corner that
demonstrates no inflammation on MRI.
MATERIALS AND METHODS
Patients. Our study comprised 50 patients with AS according to the modi-
fied New York criteria8. The patients were recruited consecutively to an
observational cohort of patients with AS who were evaluated systematical-
ly according to a standardized protocol including clinical, laboratory, and
imaging investigations9. Radiography was conducted at baseline and after
2 years and included anteroposterior and lateral views of the lumbar spine
and a lateral view of the cervical spine. MRI was conducted at baseline and
repeated prior to the 2-year radiographic followup. The patients were
assessed clinically with the Bath AS Disease Activity Score10, the Bath AS
Functional Index (BASFI)11, the patient’s global assessment, total back
pain, nocturnal back pain, and C-reactive protein. Twenty-three patients
began TNF-α inhibitor therapy and 27 patients continued standard therapy
such as NSAID and/or physical therapy.
Imaging. All the MRI was performed with 1.5 Tesla systems (Siemens,
Erlangen, Germany) using appropriate surface coils. Sagittal spine
sequences were obtained with 3–4 mm slice thickness, and 11–15 slices
were acquired. Sequence measurements were (1) T1-weighted spin-echo
[repetition time (TR) 517–618 ms, echo time (TE) 13 ms]; and (2) short-tau
inversion recovery [STIR; TR 3000–3170 ms, inversion time (TI) 140 ms,
TE 38–61 ms]. Field of view was 380–400 mm and matrix was 512 × 256
pixels. The spine was imaged in 2 parts: the upper half, comprising the
entire cervical and most of the thoracic spine; and the lower half, compris-
ing the lower portion of the thoracic spine and the entire lumbar spine.
MRI definitions. Standardized definitions of active and structural spinal
lesions observed on MRI in patients with AS have been developed by the
Spondyloarthritis Research Consortium of Canada as well as an interna-
tional working group of rheumatologists and radiologists from Canada and
Denmark12,13,14,15. The MRI readings were based on these definitions. A
vertebral corner inflammatory lesion (CIL) is defined as an increased STIR
signal at a vertebral corner that is present in at least 1 sagittal slice, which
includes the spinal canal12,16, where the bone marrow signal in the center
of the vertebra, if normal, constitutes the reference for designation of nor-
mal signal17. A CIL was defined as being completely resolved if it was
recorded as being present at baseline and then absent after the introduction
of therapy4. A CIL was defined as being persistent if it was recorded as
being present on baseline and followup MRI4.
Evaluation of images. Each MRI and radiograph was assigned a unique
computer-generated number ensuring that readers were blinded to patient
demographics and treatment. The assessments were performed on dedicat-
ed work stations using imaging software (Merge eFilm, Milwaukee, WI,
USA), and with standardized viewing conditions. MRI and radiographs
were coded in chronological order but a random number assignment
ensured that they were read independently. On MRI, the anterior vertebral
corners of the cervical (C2 lower to Th1 upper) and lumbar (Th12 lower to
S1 upper) spines were independently evaluated by 2 readers for pres-
ence/absence of CIL and for changes in these (resolved, persistent, and new
CIL). Concordant assessments were identified after completion of all reads.
Anterior vertebral corners on radiographs of the cervical (C2 lower to Th1
upper) and lumbar (Th12 lower to S1 upper) spines were evaluated inde-
pendently by 2 readers, who scored the images individually, with disagree-
ments resolved by a third reader. The thoracic spine was excluded from the
assessment because of inadequate visualization on radiographs18.
Ethics. The study was approved by the local ethical committee and per-
formed in compliance with the Helsinki Declaration. Written informed con-
sent was obtained from each patient before any study-related procedure was
performed.
Statistical analysis. The primary analysis focused on concordant data
between 2 readers, as recommended4. Vertebral corners that already
demonstrated radiographic syndesmophytes or ankylosis at baseline were
excluded. We compared the proportion of new syndesmophytes developing
at each anterior vertebral corner that demonstrated a completely resolved
CIL or a persistent CIL versus a vertebral corner that was normal by imag-
ing at baseline and at followup MRI. Patient characteristics were compared
with unpaired t-test and proportions with the Pearson chi-squared or
Fisher’s exact test. A p < 0.05 was considered statistically significant.
Statistics were analyzed in SPSS version 13 (SPSS Inc., Chicago, IL,
USA). 
RESULTS
Patient characteristics are presented in Table 1. All patients
were followed at the Department of Rheumatology,
University of Alberta, Edmonton, Canada. Anti-TNF thera-
py was initiated according to the discretion of the attending
rheumatologist but only after failure of 2 NSAID. Patients
starting anti-TNF agents (n = 23) were treated with either
infliximab 3 or 5 mg/kg (n = 11), etanercept 25 mg twice a
week (n = 10), or adalimumab 40 mg every other week (n =
2), and had NSAID on demand and physical therapy, while
patients in the standard therapy group (n = 27) were treated
only with NSAID and physical therapy. Baseline data on 18
patients receiving anti-TNF agents and 23 receiving stan-
dard therapy has been described4, while the followup data
that has since become available have not been presented
previously. In addition, a different reader pair independent-
ly assessed the MRI scans in our current study3. Followup
MRI and radiographs were done a mean of 19.2 and 27.4
months from baseline, respectively. There were no signifi-
cant differences between the 2 cohorts except that anti-TNF-
treated patients had significantly higher baseline scores for
BASFI (p = 0.046).
Development of new syndesmophytes. The total number of
anterior vertebral corners assessed in patients starting anti-
TNF therapy was 552 and in patients continuing standard
therapy was 648. Radiographic data were unavailable for 83
(15.0%) and 25 (3.9%) anterior vertebral corners in patients
treated with TNF-α inhibitors and standard therapy, respec-
tively, primarily because of lack of visualization of the
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lower part of the cervical spine. Further, 96 (17.4%) and 67
(10.3%) vertebral corners demonstrated radiographic syn-
desmophytes or ankylosis at baseline in patients treated with
TNF-α inhibitors and standard therapy, respectively. These
vertebral corners were excluded from all analyses.
At baseline, patients starting anti-TNF therapy had a
higher number of CIL [mean 1.4 (SD 1.53)] as compared to
patients receiving standard therapy [0.85 (1.8); p = 0.26;
Table 2] although this was not statistically significant.
During the study, ≥ 1 new syndesmophyte was detected
in 8 of 23 patients (34.8%) treated with TNF-α inhibitors
and in 9 of 27 patients (33.3%) receiving standard therapy
(Table 3). Patients receiving anti-TNF therapy developed
new syndesmophytes in 12 of 373 (3.2%) vertebral corners
[mean per patient 0.52 (SD 0.9)], while patients continuing
standard therapy developed new syndesmophytes in 19 of
556 (3.4%) vertebral corners [0.70 (SD 1.4)].
Association between CIL at baseline and development of
new syndesmophytes. New syndesmophytes developed
more frequently from vertebral corners that had a CIL at
baseline as compared to vertebral corners without a CIL
(Table 3). In patients starting anti-TNF therapy, new syn-
desmophytes developed in 3 of 18 (16.7%) vertebral corners
with a CIL at baseline as compared to 7 of 307 (2.2%) ver-
tebral corners without a CIL at baseline (p = 0.01). Similar
data were recorded in patients continuing standard therapy
where syndesmophytes arose from 3 of 20 (15.0%) vertebral
corners with a CIL at baseline as compared to 16 of 494
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Table 1. Patient characteristics stratified according to therapy. Results are given as mean (SD), except where
 indicated.
Characteristics TNF-α Inhibitor Standard Therapy, p
Therapy, n = 23 n = 27
Sex (male:female) 18:5 25:2 NS
Age, yrs 40.4 (12.1) 40.3 (13.4) NS
Disease duration, yrs 18.2 (11.4) 15 (10) NS
BASDAI (0-10) 5.1 (2.0) 5.0 (2.3) NS
BASFI (0-10) 4.7 (2.3) 3.2 (2.8) 0.046
Patient global (0-10) 5.2 (2.7) 4.5 (2.9) NS
Total back pain (0-10) 5.6 (2.8) 5.1 (2.4) NS
Nocturnal back pain (0-10) 5.7 (2.7) 4.6 (2.5) NS
C-reactive protein (mg/dl) 15.8 (15.1) 8.3 (13.4) NS
No. new syndesmophytes 0.52 (0.8) 0.70 (1.4) NS
Baseline mSASSS 14.5 (16.1) 10.0 (12.1) NS
mSASSS change 1.4 (1.9) 1.5 (3.1) NS
TNF: tumor necrosis factor; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; BASFI: Bath
Ankylosing Spondylitis Functional Index; mSASSS: modified Stoke Ankylosing Spondylitis Spine Score.
Table 2. Descriptive data on the number of corner inflammatory lesions (CIL) recorded in the anterior cervical and lumbar spine at baseline and at followup
MRI. Results are given for concordant and individual reads.
Concordant Reads First Reader Second Reader
TNF-α TNF-α TNF-α
Inhibitor Standard Inhibitor Standard Inhibitor Standard
Therapy Therapy Therapy Therapy Therapy Therapy
CIL Data n = 23 n = 27 n = 23 n = 27 n = 23 n = 27
Baseline MRI (total no. spinal sites) 474 599 552 648 552 648
Total number (%) of CIL 32 (6.8) 23 (3.8) 86 (15.6) 62 (9.6) 56 (10.1) 33 (5.1)
No. CIL per patient
Mean (SD) 1.4 (1.53) 0.85 (1.81) 3.74 (2.63) 2.30 (2.30) 2.43 (1.97) 1.22 (1.91)
Median (IQR) 1 (0–2) 0 (0–1) 3 (2–5) 2 (1–3) 2 (1–3.5) 1 (0–1.5)
Range 0–6 0–9 0–10 0–10 0–7 0–9
Followup MRI
Total number of CIL 11 16 53 49 25 22
CIL per patient
Mean (SD) 0.48 (1.20) 0.59 (1.45) 2.30 (2.48) 1.81 (2.06) 1.09 (2.17) 0.81 (1.66)
Median (IQR) 0 (0–0) 0 (0–1) 1 (0–4) 1 (0.5–2) 0 (0-2) 0 (0–1)
Range 0–5 0–7 0–10 0–8 0–10 0–7
No. completely resolved CIL 14 7 42 22 44 20
No. new CIL 1 3 9 9 13 9
IQR: interquartile range; MRI: magnetic resonance imaging; TNF-α: tumor necrosis factor-α. First reader: PC; second reader: SJP.
(3.2%) vertebral corners without a CIL at baseline (p =
0.03). Analysis of individual data from 1 reader confirmed
these results in the anti-TNF treatment group (12.9% vs
2.3%; p = 0.01) but not the standard therapy group (10.0%
vs 3.0%; p = 0.08), while data from another reader did not
show a significant association (anti-TNF group: 7.5% vs
2.5%, p = 0.08; standard therapy group: 5.8% vs 3.2%, 
p = 0.43).
Associations between CIL at followup and development of
new syndesmophytes. In patients starting anti-TNF therapy,
new syndesmophytes developed more frequently at those
vertebral corners where a CIL had completely resolved on
followup MRI [3 (42.9%)] as compared to those vertebral
corners where no CIL was demonstrable on either baseline
or followup MRI [7 (2.4%); p < 0.0009; Table 3]. The same
finding was observed in patients continuing standard thera-
py, although it was less striking than in patients treated with
anti-TNF therapy [1 (20%) vs 16 (3.3%); p = 0.16]. In both
patient cohorts, concordant data did not demonstrate a  single
vertebral corner that evolved into a new syndesmophyte
where a CIL was persistently demonstrable on both baseline
and followup MRI. Analysis of data from individual readers
confirmed the association between completely resolved CIL
and the development of new syndesmophytes [both readers:
4 (15.4%)] as compared to vertebral corners without CIL at
baseline [PC: 8 (2.6%), p = 0.009; SJP: 8 (2.4%), p < 0.007]
in patients starting anti-TNF therapy, while this association
was not found in patients receiving standard therapy [PC: 2
(10.5%) vs 16 (3.2%), p = 0.14; SJP: 2 (11.1%) vs 16
(3.1%), p = 0.12].
DISCUSSION
We have tested the hypothesis that complete resolution of
inflammation following anti-TNF therapy is associated with
the development of new radiographic syndesmophytes in
patients with AS. Vertebral corners with completely
resolved inflammation on followup MRI were more prone
to develop into new syndesmophytes as compared to verte-
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Table 3. Development of new syndesmophytes on radiographs of anterior cervical and lumbar spine in 50 patients with AS treated with TNF-α inhibitors or
standard therapy. Data are from concordant and individual reads and show number (%) of anterior vertebral corners associated with the presence or absence
of new syndesmophytes. Standard therapy included nonsteroidal antiinflammatory drugs and physical therapy.
TNF-α Inhibitor Therapy, n = 23 Standard Therapy, n = 27
New Syndesmophytes at New Syndesmophytes at
Followup Followup
Yes No p* Yes No p*
Concordant Reads
Baseline MRI
Vertebral corner with CIL 3 (16.7) 15 (83.3) 0.01† 3 (15.0) 17 (85.0)† 0.03†
Vertebral corner without CIL 7 (2.2) 300 (97.7) 16 (3.2) 478 (96.8)
Followup MRI
Completely resolved CIL 3 (42.9) 4 (57.1) 0.0009†† 1 (20.0) 4 (80.0)†† 0.16††
Persistent CIL 0(0) 4 (100) 0.76** 0 (0) 10 (100) 0.56**
No CIL 7 (2.4) 287 (97.6) 16 (3.3) 469 (96.7)
New CIL at followup 1 3
First reads
Baseline MRI
Vertebral corner with CIL 4 (7.5) 49 (92.5) 0.08† 3 (5.8) 49 (94.2)† 0.43†
Vertebral corner without CIL 8 (2.5) 312 (97.5) 16 (3.2) 488 (96.8)
Followup MRI
Completely resolved CIL 4 (15.4) 22 (84.6) 0.009†† 2 (10.6) 17 (89.5)†† 0.14††
Persistent CIL 0 (0) 27 (100) 0.40** 1 (3.0) 32 (97.0)** 0.95**
No CIL 8 (2.6) 303 (97.4) 16 (3.2) 481 (96.8)
New CIL at followup 9 7
Second reads
Baseline MRI
Vertebral corner with CIL 4 (12.9) 27 (87.1) 0.01† 3 (10.0) 27 (90.0) 0.08†
Vertebral corner without CIL 8 (2.3) 334 (97.7) 16 (3.0) 510 (97.0)
Followup MRI
Completely resolved CIL 4 (15.4) 22 (84.6) 0.007†† 2 (11.1) 16 (88.9) 0.12††
Persistent CIL 0 (0) 5 (100) 0.73** 1 (7.6) 12 (92.3) 0.35**
No CIL 8 (2.4) 327 (97.6) 16 (3.1) 502 (96.9)
New CIL at followup 7 7
*Pearson chi-squared test. †Compared to vertebral corners without a CIL baseline. ††Comparison of new syndesmophytes developing in vertebral corners with
a CIL that has completely resolved on followup MRI vs those vertebral corners with no CIL on either baseline or followup MRI scan. **Comparison of new
syndesmophytes developing in vertebral corners with a CIL that is present on both baseline and followup MRI vs those vertebral corners where there is no
CIL on either MRI scan. CIL: corner inflammatory lesions; MRI: magnetic resonance imaging; TNF-α: tumor necrosis factor-α. Reader 1: PC; Reader 2: SJP;
standard therapy included NSAID and physical therapy.
bral corners with no baseline inflammation, while no differ-
ences were found between vertebral corners with persistent
inflammation as compared to vertebral corners with no
baseline inflammation. While this appeared to be evident
regardless of treatment, this association was significant only
in patients who received anti-TNF therapy.
In a previous report4 that included data from patients
with AS receiving anti-TNF therapy in phase III clinical tri-
als, our finding that complete resolution of inflammation
was associated with new syndesmophytes was unexpected
and ran counter to our study hypothesis that syndesmo-
phytes would develop at sites of persistent inflammation. In
our current study, comprising an unrelated observational
cohort, we show that vertebral corners where inflammation
completely resolves on MRI are indeed more prone to
develop new syndesmophytes as compared to vertebral cor-
ners with persistent or no inflammation, despite MRI evalu-
ation being performed by 2 readers other than the ones in the
previous cohort4. In particular, we have demonstrated that
vertebral corners with persistent inflammation do not appear
to develop new syndesmophytes. Consequently, these
results support the TNF-brake hypothesis, in which TNF-α
upregulates DKK-1, a major negative regulator of
osteoblastogenesis through the Wnt signaling pathway4.
Reduced levels of active TNF due to anti-TNF therapy may
therefore not only promote resolution of inflammation but
also enhance osteoblastogenesis because of downregulation
of DKK-1.
The higher frequency of CIL at baseline and of com-
pletely resolved CIL in patients treated with TNF-α
inhibitors but without excess development of syndesmo-
phytes as compared to patients receiving standard therapies
might appear to be contradictory with the TNF-brake
hypothesis. Moreover, data from phase III trials of anti-TNF
therapy have not demonstrated any overall difference in
radiographic progression, as measured with the Modified
Stoke AS Spinal Score, as compared to historical controls
receiving standard therapy19,20,21. The results from the clin-
ical trials can be reconciled with the data and conclusions
from our study by first considering that lesions in AS evolve
from early inflammatory lesions with features of synovial
and/or subchondral marrow inflammation that may include
erosive changes, followed by reparative processes that
include fat infiltration, cartilage metaplasia, and the forma-
tion of new bone through endochondral ossification22,23,24.
Lesions at all these stages of evolution may be present
simultaneously in the individual patient with established AS
who is characteristic of patients recruited to phase III trials
of anti-TNF therapy. It may be possible that very early
inflammatory lesions resolve completely without any seque-
lae if anti-TNF therapy is introduced before signaling path-
ways leading to reparative processes, especially new bone
formation, have been triggered25. On the other hand, once a
lesion has become more advanced and reparation is well
under way, introduction of anti-TNF alleviates inflamma-
tion but now accelerates reparation and new bone formation
through its effects on DKK-1 and other regulatory mole-
cules. For an individual patient, the overall development of
new bone during anti-TNF therapy may therefore depend on
the balance between the number of early and more mature
inflammatory lesions.
The focus on the assessment of lesions that are concor-
dantly detected by 2 readers is in our view important in stud-
ies using MRI to detect these lesions as compared to focus-
ing on individual reader data, which, as in this analysis, may
show discrepancy. This reflects the fact that inflammatory
lesions at vertebral corners can be small and/or demonstrate
only a slight alteration in signal intensity on STIR
sequences. Reliable assessment of lesions in the cervical
spine is particularly difficult because of the small size of the
vertebrae and the large field of view, which is currently stan-
dard for MRI in spondyloarthritis. In addition, phase-encod-
ing artefact constitutes a significant limitation in the reliable
assessment of inflammatory lesions in the anterior vertebral
corners of the lumbar spine. Specifically, MRI is subject to
physiological motion artefacts, so that flowing blood in the
inferior vena cava and the abdominal aorta may cause spu-
rious signal that mimics anterior vertebral corner inflamma-
tory lesions in the lumbar spine.
The necessity to focus on concordant data, especially
reliable detection of resolution of inflammation, together
with the small number of new syndesmophytes, limits the
sample size available for analysis and constitutes a limita-
tion of our study, so the results should be interpreted with
caution. Moreover, the small sample size precludes the con-
sideration of potential confounders previously shown to
influence disease progression in the spine of patients with
AS, especially baseline radiographic damage.
The majority of new syndesmophytes develops at sites
without inflammation on baseline and followup scans and
this may well point to noninflammatory pathways of new
bone formation, as pointed out by others26. However, it is
important to note that MRI has limited sensitivity for the
detection of spinal inflammatory lesions evident on
histopathology1, with only about half of such lesions being
evident on STIR MRI. In addition, MRI scans limited to 1
or 2 timepoints can only reflect a limited snapshot of events
that may evolve rapidly with time.
We tested and confirmed the hypothesis that vertebral
corners with resolved inflammation on MRI were more like-
ly to develop into new syndesmophytes as compared to ver-
tebral corners with no inflammation. The results support a
biomolecular model in which TNF-α suppresses bone for-
mation through upregulation of DKK-1 in established
inflammatory lesions where bone signaling pathways medi-
ated by Wnt, BMP, and possibly other proteins are activated
during the course of inflammation. An important prediction
of the model that should now be tested is that anti-TNF ther-
5Pedersen, et al: AS and bone formation
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apy used very early in the course of SpA will prevent new
bone formation by abrogating inflammation prior to activa-
tion of bone signaling pathways.
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